cabergoline has been researched along with Argentaffinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borson-Chazot, F; Ilie, MD; Raverot, G; Raverot, V; Tronc, F; Vasiljevic, A | 1 |
| Colao, A; De Martino, MC; Faggiano, A; Franco, R; Kaltsas, GA; Marino, FZ; Napolitano, M; Negri, M; Patalano, R; Pivonello, C; Pivonello, R; Rocco, G; Rousaki, P; Sarnataro, M; Sciammarella, C | 1 |
| Colao, A; Ferone, D; Lamberts, SW; Pivonello, R | 1 |
3 other study(ies) available for cabergoline and Argentaffinoma
| Article | Year |
|---|---|
Cabergoline in severe ectopic or occult Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adult; Aged; Cabergoline; Carcinoid Tumor; Cushing Syndrome; Dopamine Agonists; Female; Humans; Hydrocortisone; Ketoconazole; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Intraductal Neoplasms; Rectal Neoplasms; Steroid Synthesis Inhibitors; Thymus Neoplasms; Treatment Outcome | 2019 |
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Topics: Antineoplastic Agents; Cabergoline; Carcinoid Tumor; Cell Line, Tumor; Cell Survival; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Everolimus; Humans; Lung Neoplasms; Octreotide; Receptors, Dopamine D2; Receptors, Somatostatin; Signal Transduction; Somatostatin; TOR Serine-Threonine Kinases | 2017 |
Cabergoline plus lanreotide for ectopic Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adult; Cabergoline; Carcinoid Tumor; Cushing Syndrome; Drug Therapy, Combination; Ergolines; Humans; Lung Neoplasms; Male; Peptides, Cyclic; Somatostatin | 2005 |